title: Effectiveness and safety of intravenous iloprost for severe persistent pulmonary hypertension of the newborn.
abstract: OBJECTIVE
  The aims of this study were to determine the effectiveness (oxygenation), safety (hemodynamic status) and short term outcomes of intravenous iloprost (IVI) administration as a rescue therapy in severe persistent pulmonary hypertension of the newborn (PPHN).
  
  
  METHODS
  Retrospective medical records review.
  
  
  METHODS
  Tertiary neonatal intensive care unit at Songklanagarind Hospital, Songkhla Province, Hat Yai, Thailand.
  
  
  METHODS
  Newborns who received IVI as an adjunctive therapy for treatment of severe PPHN, as defined by an oxygen index (OI) of >20 and without response to conventional therapies.
  
  
  METHODS
  The change of OI and alveolar-arterial oxygen difference before and after commencement of IVI.
  
  
  RESULTS
  33 neonates with severe PPHN at a median gestation of 39 weeks and a baseline OI of 40 (range, 21-101) received IVI. The median OI and alveolar-arterial oxygen difference had a statistically significant decrease after 2 hours of treatment and continued to decline thereafter (P<0.05). All infants received one or more inotropic medications and volume expanders to provide blood pressure support with no statistically significant difference of blood pressure and heart rate before and after IVI treatment. The mortality rate was 15.2%, all of them had initially severe hypoxemia with a median OI of 53.6.
  
  
  CONCLUSIONS
  Triglyceride and non-high-density lipoprotein cholesterol are better than low-density lipoprotein cholesterol as predictors of cardiovascular disease risk factors in Chinese Han children and adolescents.
authors.affiliation: Division of Neonatology, Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand. Correspondence to: Dr Waricha Janjindamai, Division of Neonatology, Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, 15 Kanjanavanit Road, Hat Yai, Songkhla, Thailand, 90110. jwaricha@medicine.psu.ac.th.
authors.forename: Waricha
authors.initials: W
authors.lastname: Janjindamai
authors.forename: Anucha
authors.initials: A
authors.lastname: Thatrimontrichai
authors.forename: Gunlawadee
authors.initials: G
authors.lastname: Maneenil
authors.forename: Prasin
authors.initials: P
authors.lastname: Chanvitan
authors.forename: Supaporn
authors.initials: S
authors.lastname: Dissaneevate
mesh_terms: D061605:Administration, Intravenous; D005260:Female; D006801:Humans; D016285:Iloprost / Q000008:administration & dosage* / Q000009:adverse effects*; D007231:Infant, Newborn; D008297:Male; D010100:Oxygen / Q000378:metabolism; D010547:Persistent Fetal Circulation Syndrome / Q000188:drug therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D014665:Vasodilator Agents; D016285:Iloprost; D010100:Oxygen